Pulmatrix closes $1M Series B preferred placement as part of planned merger with Eos

Pulmatrix, Inc.

Gross proceeds of approximately $1 million from Series B Preferred Stock issued to Eos affiliate.
Conversion price of $2.20 per share; convertible 90 days after issuance.
Placement is an initial step in the planned merger with Eos SENOLYTIX; definitive agreement signed.
Net proceeds to be used for working capital and general corporate purposes.
Interim CEO Peter Ludlum highlighted the investment as part of the ongoing merger process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.